BeOne Medicines annual free cash flow
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BeOne Medicines Free Cash Flow (FCF) History (ONC)
BeOne Medicines reported $941.7M in free cash flow for fiscal 2025, an increase of $1.58B from the previous fiscal year, with a free cash flow margin of 17.63%.
View full BeOne Medicines company overviewBeOne Medicines free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $941.7M | $1.58B | — | +17.63% |
| 2024 | 2024-12-31 | −$633.3M | $1.09B | — | −16.62% |
| 2023 | 2023-12-31 | −$1.72B | $102.7M | — | −69.93% |
| 2022 | 2022-12-31 | −$1.82B | −$260.4M | — | −128.68% |
| 2021 | 2021-12-31 | −$1.56B | −$160.7M | — | −132.76% |
| 2020 | 2020-12-31 | −$1.40B | −$561.1M | — | −453.57% |
| 2019 | 2019-12-31 | −$839.9M | −$221.9M | — | −196.14% |
| 2018 | 2018-12-31 | −$618.0M | −$584.4M | — | −311.77% |
| 2017 | 2017-12-31 | −$33.6M | $79.4M | — | −14.10% |
| 2016 | 2016-12-31 | −$113.0M | −$67.9M | — | −10562.15% |
| 2015 | 2015-12-31 | −$45.2M | −$35.8M | — | −512.22% |
| 2014 | 2014-12-31 | −$9.3M | — | — | −71.71% |
BeOne Medicines quarterly free cash flow
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $435.3M | $215.6M | +98.09% | +25.53% |
| Q1 2026 | 2026-03-31 | $160.5M | $172.9M | — | +10.61% |
| Q4 2025 | 2025-12-31 | $379.8M | $397.1M | — | +25.35% |
| Q3 2025 | 2025-09-30 | $354.5M | $299.8M | +547.86% | +25.10% |
| Q2 2025 | 2025-06-30 | $219.8M | $425.3M | — | +16.71% |
| Q1 2025 | 2025-03-31 | −$12.3M | $452.8M | — | −1.10% |
| Q4 2024 | 2024-12-31 | −$17.3M | $361.3M | — | −1.54% |
| Q3 2024 | 2024-09-30 | $54.7M | $290.7M | — | +5.46% |
| Q2 2024 | 2024-06-30 | −$205.5M | $209.8M | — | −22.12% |
| Q1 2024 | 2024-03-31 | −$465.1M | $224.2M | — | −61.88% |
| Q4 2023 | 2023-12-31 | −$378.6M | $61.0M | — | −59.68% |
| Q3 2023 | 2023-09-30 | −$236.0M | $434.5M | — | −30.21% |
| Q2 2023 | 2023-06-30 | −$415.4M | $14.9M | — | −69.78% |
| Q1 2023 | 2023-03-31 | −$689.4M | −$407.7M | — | −153.94% |
| Q4 2022 | 2022-12-31 | −$439.5M | $183.3M | — | −115.64% |
| Q3 2022 | 2022-09-30 | −$670.6M | −$107.8M | — | −172.99% |
| Q2 2022 | 2022-06-30 | −$430.2M | $28.5M | — | −125.96% |
| Q1 2022 | 2022-03-31 | −$281.7M | −$364.4M | — | −91.87% |
| Q4 2021 | 2021-12-31 | −$622.8M | −$255.8M | — | −291.07% |
| Q3 2021 | 2021-09-30 | −$562.8M | −$187.8M | — | −272.60% |
| Q2 2021 | 2021-06-30 | −$458.8M | −$163.3M | — | −305.88% |
| Q1 2021 | 2021-03-31 | $82.7M | $446.2M | — | +13.65% |
| Q4 2020 | 2020-12-31 | −$367.0M | −$84.4M | — | −366.66% |
| Q3 2020 | 2020-09-30 | −$374.9M | −$79.0M | — | −411.64% |
| Q2 2020 | 2020-06-30 | −$295.5M | −$228.0M | — | −450.29% |
| Q1 2020 | 2020-03-31 | −$363.5M | −$169.7M | — | −698.20% |
| Q4 2019 | 2019-12-31 | −$282.6M | −$65.5M | — | −496.81% |
| Q3 2019 | 2019-09-30 | −$295.9M | −$137.0M | — | −590.11% |
| Q2 2019 | 2019-06-30 | −$67.5M | $60.2M | — | −27.76% |
| Q1 2019 | 2019-03-31 | −$193.8M | −$79.6M | — | −249.00% |
| Q4 2018 | 2018-12-31 | −$217.1M | −$292.0M | — | −370.12% |
| Q3 2018 | 2018-09-30 | −$158.9M | −$146.9M | — | −293.17% |
| Q2 2018 | 2018-06-30 | −$127.8M | −$72.1M | — | −241.93% |
| Q1 2018 | 2018-03-31 | −$114.2M | −$73.4M | — | −350.90% |
| Q4 2017 | 2017-12-31 | $74.8M | $109.0M | — | — |
| Q3 2017 | 2017-09-30 | −$12.0M | $19.0M | — | −5.43% |
| Q2 2017 | 2017-06-30 | −$55.7M | −$31.0M | — | — |
| Q1 2017 | 2017-03-31 | −$40.8M | −$17.6M | — | — |
| Q4 2016 | 2016-12-31 | −$34.2M | −$14.0M | — | — |
| Q3 2016 | 2016-09-30 | −$31.0M | −$20.2M | — | −7877.35% |
| Q2 2016 | 2016-06-30 | −$24.7M | −$13.0M | — | −6287.79% |
| Q1 2016 | 2016-03-31 | −$23.1M | −$16.2M | — | −3418.61% |
| Q4 2015 | 2015-12-31 | −$20.2M | — | — | −431.56% |
| Q3 2015 | 2015-09-30 | −$10.7M | — | — | −778.48% |
| Q2 2015 | 2015-06-30 | −$11.7M | — | — | −847.46% |
| Q1 2015 | 2015-03-31 | −$6.9M | — | — | −503.48% |
BeOne Medicines free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$1.40B to $941.7M, a net increase of $2.34B. BeOne Medicines's latest reported quarter, Q2 2026, generated $435.3M in free cash flow, an increase of 98.09% year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review BeOne Medicines filings at SEC.gov ↗